semaglutide new england journal of medicine Once-Weekly in Adults with Overweight or Obesity In the SURMOUNT-5 phase 3b

Haahtela T, Holgate S, Pawankar R, Akdis CA, Benjaponpitak S, Caraballo L, Demain J, Portnoy J, von Hertzen L, WAO Special Committee on Climate Change and Biodiversity

Current practice Although authoritative health and medical entities recommend comprehensive lifestyle modification as part of the treatment plan for obesity, the use of such therapies before or to support GLP-1 use is not widespread in practice

Garland, TX

When you inject a substance, you need absolute certainty about what is in that vial

Taken together, these points underscore FDAs view that compounded GLP1 products present concrete patient-safety and supplychain risks that warrant heightened scrutiny